2. Search Result
Search Result
Results for "

squalene synthase

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

5

Natural
Products

1

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103087
    FIN56
    Maximum Cited Publications
    24 Publications Verification

    		 Ferroptosis Others
    FIN56 is a specific inducer of ferroptosis. FIN56 induces ferroptosis by inducing degradation of GPX4. FIN56 also binds to and activates squalene synthase .
    FIN56
  • HY-16274
    Lapaquistat acetate
    1 Publications Verification

    TAK-475

    		 Farnesyl Transferase Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-100313A
    YM-53601
    5 Publications Verification

    		 Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-116290
    Zaragozic acid A
    1 Publications Verification

    Squalestatin S1

    		 Endogenous Metabolite Metabolic Disease
    Zaragozic acid A is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase. Zaragozic acid A is an inhibitor of acute hepatic cholesterol synthesis in mouse (IC50 = 6 μM) .
    Zaragozic acid A
  • HY-B2097
    Incadronate disodium

    YM 175; Bisphonal

    		 Farnesyl Transferase Metabolic Disease
    Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
    Incadronate disodium
  • HY-100313
    YM-53601 free base

    		Farnesyl Transferase HCV Metabolic Disease
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 free base
  • HY-178158
    SQS-IN-1

    		Farnesyl Transferase Apoptosis DNA/RNA Synthesis Cancer
    SQS-IN-1 is a squalene synthase (SQS) inhibitor. SQS-IN-1 exhibits potent and broad-spectrum anti-proliferative effects on both mouse and human lung cancer cell lines. SQS-IN-1 inhibits DNA replication and the cell cycle, causing mitochondrial hyperpolarization and inducing cell apoptosis. SQS-IN-1 inhibits cell migration and invasion. SQS-IN-1 can be used to the study of lung cancer .
    SQS-IN-1
  • HY-163452
    Squalene synthase-IN-2

    		Farnesyl Transferase Metabolic Disease
    Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC50 values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .
    Squalene synthase-IN-2
  • HY-149405
    Squalene synthase-IN-1

    		Others Metabolic Disease
    Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent acting through Squalene Synthase inhibition. Squalene synthase-IN-1 exhibits an outstanding antioxidant and anti-inflammatory activity. Squalene synthase-IN-1 displays a significant reduction not only of glucose but also of oxidative stress levels, while it did not cause any toxicity .
    Squalene synthase-IN-1
  • HY-116290A
    Zaragozic acid A trisodium

    Squalestatin S1 trisodium

    		 Farnesyl Transferase Fungal Endogenous Metabolite Others
    Zaragozic acid A trisodium is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase .
    Zaragozic acid A trisodium
  • HY-124374
    J-104123

    		Farnesyl Transferase Metabolic Disease
    J-104123 is an inhibitor of squalene synthase with monocarboxylic acid structure. J-104123 can lower serum cholesterol level in dog models .
    J-104123
  • HY-16108A
    BMS-187745 tripotassium

    		Farnesyl Transferase Metabolic Disease
    BMS-187745 tripotassium (Compound 1) is a potent squalene synthase inhibitor .
    BMS-187745 tripotassium
  • HY-126871
    Zaragozic acid D2

    		Farnesyl Transferase Metabolic Disease Cancer
    Zaragozic acid D2 is the inhibitor for squalene synthase and Ras farnesyl-protein transferase (Ras FPTase), with IC50 of 2 nM and 100 nM, respectively. Zaragozic acid D2 is potentially ameliorating hypercholesterolemia and Ras-induced cancer .
    Zaragozic acid D2
  • HY-116595
    J-104118

    		Farnesyl Transferase Metabolic Disease
    J-104118 is a potent and orally active squalene synthase (SQS) inhibitor with an IC50 of 0.52 nM. J-104118 inhibits cholesterol synthesis in mice. J-104118 can be used for cholesterol-lowering research .
    J-104118
  • HY-123404
    L-731128

    		Fungal Farnesyl Transferase Infection
    L-731128 is a novel alkyl citrate. L-731128 can be isolated as a minor component of Sporormiella intermedia (MF 5447, ATCC 20985) fermentations. L-731128 is a potent squalene synthase inhibitor, with an IC50 value of 767 nM .
    L-731128
  • HY-178088
    L-731120

    		Fungal Drug Derivative Drug Metabolite Infection Metabolic Disease
    L-731120 is an alkyl citrate zargozaga acid A analogue, which is secondary metabolite produced by fungal fermentation. L-731120 shows inhibitory activity against squalene synthase (SQS) (IC50 = 260 nM). L-731120 can inhibit the synthesis of cholesterol in the liver. L-731120 can be used for the research of infection and metabolic disease, such as hypercholesterolemia .
    L-731120
  • HY-100299A
    RPR107393

    		Farnesyl Transferase Cardiovascular Disease Metabolic Disease
    RPR107393 is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 reduces plasma cholesterol in rats and marmosets. RPR107393 can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis .
    RPR107393
  • HY-100299
    RPR107393 free base

    		Farnesyl Transferase Cardiovascular Disease Metabolic Disease
    RPR107393 free base is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 free base inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 free base reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 free base reduces plasma cholesterol in rats and marmosets. RPR107393 free base can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis [1][2].
    RPR107393 free base
  • HY-N13888
    Schizostatin

    		Farnesyl Transferase Metabolic Disease
    Schizostatin is a squalene synthase inhibitor with an IC50 of 0.84 μM .
    Schizostatin
  • HY-125324
    Squalestatin 3

    		Endogenous Metabolite Cardiovascular Disease
    Squalestatin 3 is a secondary metabolite, which can be isolated from Phoma. Squalestatin 3 is an inhibitor for squalene synthase with an IC50 of 6 nM .
    Squalestatin 3
  • HY-135625
    BPH-1218

    		Parasite Infection
    BPH-1218 is an inhibitor of squalene synthase (SQS), with the IC50 of 31 nM and 64 nM for TcSQS and HsSQS, respectively, that can be used as an anti-infective agent .
    BPH-1218
  • HY-103087R
    FIN56 (Standard)

    		Reference Standards Ferroptosis Others
    FIN56 (Standard) is the analytical standard of FIN56 (HY-103087). This product is intended for research and analytical applications. FIN56 is a specific inducer of ferroptosis. FIN56 induces ferroptosis by inducing degradation of GPX4. FIN56 also binds to and activates squalene synthase .
    FIN56 (Standard)
  • HY-100313AR
    YM-53601 (Standard)

    		Farnesyl Transferase Reference Standards HCV Infection Metabolic Disease
    YM-53601 (Standard) is the analytical standard of YM-53601 (HY-100313A). This product is intended for research and analytical applications. YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 (Standard)
  • HY-123405
    YM-75440

    		Endogenous Metabolite Others
    YM-75440 is an orally active inhibitor of squalene synthase.
    YM-75440
  • HY-123746
    E5700

    		Farnesyl Transferase Fungal Parasite Infection
    E5700 is an orally active squalene synthase inhibitor, antimalarial agent and antifungal agent with an IC50 of 0.49 nM (without PPi) against squalene synthase from T. cruzi epimastigotes. E5700 shows antiparasitic activities against Trypanosoma cruzi. E5700 inhibits the growth and alters the lipid prolife and the ultrastructure of a multiple agent-resistant C. tropicalis strain. E5700 is a potent and selective inhibitor of the growth of Leishmania amazonensis .
    E5700

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: